Clinical Trial Detail

NCT ID NCT04364048
Title Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rachel Sanborn
Indications

lung non-small cell carcinoma

Therapies

Pemetrexed Disodium

Durvalumab

Paclitaxel

Etoposide

Docetaxel

Carboplatin

Cisplatin

Age Groups: adult senior

No variant requirements are available.